NO20091618L - Bicykliske triazoler som proteinkinasemodulatorer - Google Patents

Bicykliske triazoler som proteinkinasemodulatorer

Info

Publication number
NO20091618L
NO20091618L NO20091618A NO20091618A NO20091618L NO 20091618 L NO20091618 L NO 20091618L NO 20091618 A NO20091618 A NO 20091618A NO 20091618 A NO20091618 A NO 20091618A NO 20091618 L NO20091618 L NO 20091618L
Authority
NO
Norway
Prior art keywords
protein kinase
kinase modulators
bicyclic
bicyclic triazoles
triazoles
Prior art date
Application number
NO20091618A
Other languages
English (en)
Norwegian (no)
Inventor
Pierre-Yves Bounaud
Christopher Ronald Smith
Elizabeth Anne Jefferson
Original Assignee
Sgx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sgx Pharmaceuticals Inc filed Critical Sgx Pharmaceuticals Inc
Publication of NO20091618L publication Critical patent/NO20091618L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20091618A 2006-10-23 2009-04-23 Bicykliske triazoler som proteinkinasemodulatorer NO20091618L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86255206P 2006-10-23 2006-10-23
US87030906P 2006-12-15 2006-12-15
US91376607P 2007-04-24 2007-04-24
US95284007P 2007-07-30 2007-07-30
PCT/US2007/081841 WO2008051808A2 (en) 2006-10-23 2007-10-18 Bicyclic triazoles as protein kinase modulators

Publications (1)

Publication Number Publication Date
NO20091618L true NO20091618L (no) 2009-05-22

Family

ID=38956385

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091618A NO20091618L (no) 2006-10-23 2009-04-23 Bicykliske triazoler som proteinkinasemodulatorer

Country Status (25)

Country Link
US (1) US8507489B2 (es)
EP (1) EP2084162B1 (es)
JP (1) JP5378222B2 (es)
KR (1) KR20090071612A (es)
AR (1) AR063520A1 (es)
AU (1) AU2007309149C1 (es)
BR (1) BRPI0717320A2 (es)
CA (1) CA2667428A1 (es)
CO (1) CO6190620A2 (es)
CR (1) CR10803A (es)
DK (1) DK2084162T3 (es)
EA (1) EA200970403A1 (es)
ES (1) ES2393130T3 (es)
IL (1) IL197958A0 (es)
MA (1) MA30871B1 (es)
MX (1) MX2009004059A (es)
NO (1) NO20091618L (es)
NZ (1) NZ575336A (es)
PE (1) PE20080893A1 (es)
PL (1) PL2084162T3 (es)
PT (1) PT2084162E (es)
SV (1) SV2009003235A (es)
TN (1) TN2009000142A1 (es)
TW (1) TW200835492A (es)
WO (1) WO2008051808A2 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8792501A1 (es) * 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
TWI365185B (en) 2008-07-24 2012-06-01 Lilly Co Eli Amidophenoxyindazoles useful as inhibitors of c-met
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
EP2165710A1 (en) 2008-09-19 2010-03-24 Institut Curie Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor
JP2012509342A (ja) 2008-11-20 2012-04-19 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換ピロロ［２，３−ｂ］−ピリジンおよび−ピラジン
FR2941950B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941949B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941951B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941952B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
CA2771432A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
AU2010338712B2 (en) 2009-12-31 2015-04-02 Hutchison Medipharma Limited Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
US20130072495A1 (en) 2010-05-14 2013-03-21 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
AR085183A1 (es) * 2010-07-30 2013-09-18 Lilly Co Eli Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
UY33549A (es) * 2010-08-10 2012-01-31 Glaxo Group Ltd Quinolil aminas como agentes inhibidores de las quinasas
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
CN102532141A (zh) 2010-12-08 2012-07-04 中国科学院上海药物研究所 [1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途
ES2627788T3 (es) 2011-01-11 2017-07-31 Sunovion Pharmaceuticals Inc. Compuestos heteroarilo y procedimientos de uso de los mismos
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
CN103459396B (zh) * 2011-02-10 2015-08-19 诺瓦提斯公司 作为c-Met酪氨酸激酶抑制剂的[1,2,4]三唑并[4,3-b]哒嗪化合物
US20140088114A1 (en) 2011-05-16 2014-03-27 OSI Pharmaceuticals ,LLC Fused bicyclic kinase inhibitors
MX339302B (es) * 2011-09-15 2016-05-19 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
CN103958509B (zh) * 2011-09-15 2015-12-23 诺华股份有限公司 作为酪氨酸激酶抑制剂的6-取代的3-(喹啉-6-基硫代)-[1,2,4]三唑并[4,3-a]吡啶化合物
KR20140146086A (ko) 2012-04-03 2014-12-24 노파르티스 아게 티로신 키나제 억제제 조합물 및 그의 용도
ES2894830T3 (es) 2012-04-03 2022-02-16 Novartis Ag Productos combinados con inhibidores de tirosina·cinasa y su uso
CN103122000B (zh) * 2012-09-03 2013-12-25 中美冠科生物技术（太仓）有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
WO2014089904A1 (en) * 2012-12-10 2014-06-19 Abbvie Inc. Triazinone compounds
WO2014164195A1 (en) 2013-03-13 2014-10-09 Avon Products, Inc Tyrosinase inhibitors
CA2948765A1 (en) * 2013-03-13 2014-09-18 F. Hoffmann-La Roche Ag Intermediate (4-bromo-2-fluorophenyl)-1h-imidazoyl derivatives for use in a process to synthesize benzoxazepin compounds
WO2014158943A1 (en) * 2013-03-13 2014-10-02 Avon Products, Inc Tyrosinase inhibitors
US20150174034A1 (en) 2013-03-13 2015-06-25 Avon Products, Inc. Tyrosinase inhibitors
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
JP6355719B2 (ja) * 2013-05-10 2018-07-11 ジエンス ハンセン ファーマセウティカル カンパニー リミテッド ［１，２，４］トリアゾール［４，３−ａ］ピリジン誘導体、その製造方法またはその医薬応用
CN105272995B (zh) 2015-09-24 2017-10-27 上海海聚生物科技有限公司 喹啉类衍生物、其药物组合物、制备方法及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604091A (en) 1984-03-01 1997-02-18 Microgenics Corporation Methods for protein binding enzyme complementation
JPS60194443A (ja) * 1984-03-16 1985-10-02 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
EP0228061A3 (en) 1985-12-23 1988-12-14 Takeda Chemical Industries, Ltd. Cephem compounds
JPS62228086A (ja) * 1985-12-23 1987-10-06 Takeda Chem Ind Ltd セフエム化合物
GB9918035D0 (en) 1999-07-30 1999-09-29 Novartis Ag Organic compounds
WO2002083139A1 (en) * 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
WO2002083675A2 (en) * 2001-04-10 2002-10-24 Merck Sharp & Dohme Limited Inhibitors of akt activity
US20030229453A1 (en) 2002-04-09 2003-12-11 Antonysamy Stephen Suresh Crystals and structures of PAK4KD kinase PAK4KD
KR101075812B1 (ko) * 2002-12-18 2011-10-25 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서의 트리아졸로피리다진
US7122548B2 (en) * 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
JP2008508304A (ja) * 2004-07-27 2008-03-21 エスジーエックス ファーマシューティカルズ、インコーポレイテッド 縮合環ヘテロ環キナーゼ調節因子
PT1784396E (pt) 2004-08-26 2011-01-27 Pfizer Compostos amino-heteroarílicos substituídos com pirazole como inibidores de proteína quinases
ATE519488T1 (de) 2004-12-27 2011-08-15 Novartis Ag Aminopyrazin-analoga zur behandlung von glaukomen und anderen durch rho-kinase verursachten krankheiten

Also Published As

Publication number Publication date
PE20080893A1 (es) 2008-08-26
MA30871B1 (fr) 2009-11-02
AU2007309149C1 (en) 2013-04-04
CO6190620A2 (es) 2010-08-19
PL2084162T3 (pl) 2013-01-31
AR063520A1 (es) 2009-01-28
CR10803A (es) 2009-06-16
PT2084162E (pt) 2012-10-09
AU2007309149A1 (en) 2008-05-02
JP5378222B2 (ja) 2013-12-25
EP2084162B1 (en) 2012-09-12
US8507489B2 (en) 2013-08-13
EA200970403A1 (ru) 2009-10-30
MX2009004059A (es) 2009-04-27
JP2010507578A (ja) 2010-03-11
DK2084162T3 (da) 2012-10-01
BRPI0717320A2 (pt) 2013-10-22
IL197958A0 (en) 2009-12-24
NZ575336A (en) 2012-04-27
AU2007309149B2 (en) 2012-09-06
SV2009003235A (es) 2009-10-15
TN2009000142A1 (en) 2010-10-18
KR20090071612A (ko) 2009-07-01
ES2393130T3 (es) 2012-12-18
EP2084162A2 (en) 2009-08-05
TW200835492A (en) 2008-09-01
WO2008051808A3 (en) 2008-07-24
US20090258855A1 (en) 2009-10-15
WO2008051808A2 (en) 2008-05-02
CA2667428A1 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
NO20091618L (no) Bicykliske triazoler som proteinkinasemodulatorer
MX2009004060A (es) Moduladores de proteina cinasa de triazolpiridazina.
NO20031270L (no) Imidazolderivater som Raf-kinaseinhibitorer
NO20070908L (no) Sammensmeltede ringheterocykelkinasemodulatorer
WO2007079164A3 (en) Protein kinase inhibitors
NO20071619L (no) Fremgangsmate for fremstilling av indazol forbindelse
UA95244C2 (ru) Соединения и способ модулирования активности киназ, и показания для их применения
MA29935B1 (fr) Inhibiteurs de l'activite de akt
EA200602241A1 (ru) Замещённые индазолы, композиции, содержащие указанные индазолы, способ их получения и применение
MX2009012623A (es) Moduladores de cinasa heterociclicos.
MY148468A (en) Compounds and methods for kinase modulation, and indications therefor
MX2009006688A (es) Compuestos y metodos para modulacion de cinasas, e indicaciones para ello.
MA31167B1 (fr) Inhibiteurs de l'activite de akt
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
WO2007109045A8 (en) Heterocyclic organic compounds for the treatment of in particular melanoma
NO20084435L (no) C-MET proteinkinaseinhibitorer
NO20093009L (no) Kondensert ring heterocykel kinase modulatorer
WO2008033562A3 (en) Kinase inhibitor compounds
NO20071901L (no) Substituerte bisykliske imidazo-3-ylamin sammensetninger
EA201000149A1 (ru) Производные 1-фенил-2-пиридинилалкиловых спиртов в качестве ингибиторов фосфодиэстераз
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
NO20083918L (no) Dihydridiazepiner anvendelige som inhibitorer av proteinkinaser
NO20082476L (no) Bicykliske forbindelser med kinaseinhiberende aktivitet
AU2012283775A8 (en) Inhibitors of Bruton's tyrosine kinase
EA200870292A1 (ru) Соединения на основе имидазола, композиции, содержащие их, и способы их применения

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application